Aptivus Limited Part D Formulary Coverage May Reflect Approval Timing
Executive Summary
Boehringer Ingelheim's experience with Part D placement for its HIV therapy Aptivus points to the importance of approval timing in securing formulary coverage on Medicare drug plans
You may also be interested in...
Branded Antidepressants Face Challenges With Part D Formulary Positions
The Centers for Medicare & Medicaid Services appears to be interpreting its "all or substantially all" policy for Part D plan coverage of antidepressants as allowing sponsors to include the majority of agents on high cost-sharing tiers, according to analysis of plan formularies conducted by "The Pink Sheet."
Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study
Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)
Medicare Part D Formularies May Omit Lexapro Or Celexa, CMS Says
Medicare Part D plans will not be required to include both Forest antidepressants Lexapro and Celexa in their formularies, the Centers for Medicare & Medicaid Services said in a supplement to a question and answer document on the program